If we see no safety issues, and are able to detect some engraftment of our cells to the photoreceptor / Bruch's membrane, we will obviously be dealing from a much stronger valuation and negotiating position. It is quite possible that within about 12 weeks of commencement of the trials, we may have a pretty interesting set of data to evaluate and discuss, covering an early look at a total of 6 patients between the two trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.